...
首页> 外文期刊>The Biochemical Journal >Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization
【24h】

Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization

机译:纯化的重组胰岛素降解酶降解淀粉样蛋白β,但不促进其寡聚

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Amyloid beta -protein (A beta) has been implicated as an early and essential factor in the pathogenesis of Alzheimer's disease. Although its cellular production has been studied extensively, little is known about A beta clearance. Recently, insulin-degrading enzyme (IDE), a 110-kDa metalloendopeptidase, was found to degrade both endogenously secreted and synthetic A beta peptides. Surprisingly, IDE-mediated proteolysis of [I-125]A beta>(*) over bar * (1-40) in microglial cell-culture media was accompanied by the formation of I-125-labelled peptides with higher apparent molecular masses, raising the possibility that the degradation products act as 'seeds' for A beta oligomerization. To directly address the role of IDE in AP degradation and oligomerization, we investigated the action of purified recombinant wild-type and catalytically inactive IDEs. Our data demonstrate that (i) IDE alone is sufficient to cleave purified A beta that is either unlabelled, iodinated or S-35- Labelled; (ii) the initial cleavage sites are His(14)-Gln(15), Phe(19)-Phe(20) and Phe(20)-Ala(21); and (iii) incubation of IDE with [125I]AB, but not with [S-35]-A beta, leads to the formation of slower migrating species on gels. Since iodination labels N-terminal fragments of A beta, and 35S labels C-terminal products, we analysed unlabelled synthetic fragments of A beta and determined that only the N-terminal fragments migrate with anomalously high molecular mass. These results indicate that IDE alone is sufficient to degrade A beta at specific sites, and that its degradation products do not promote oligomerization of the intact A beta peptide. [References: 42]
机译:淀粉样β蛋白(A beta)已被认为是阿尔茨海默氏病发病机理中的早期必不可少的因素。尽管已经对其细胞产生进行了广泛研究,但对Aβ清除知之甚少。最近,发现一种110 kDa的金属内肽酶胰岛素降解酶(IDE)可以降解内源性分泌和合成的Aβ肽。出乎意料的是,在小胶质细胞培养基中,IDE介导的[I-125] A beta>(*)在bar *(1-40)上的蛋白水解伴随着I-125标记的具有更高表观分子质量的肽的形成,增加了降解产物充当A beta寡聚的“种子”的可能性。为了直接解决IDE在AP降解和低聚中的作用,我们研究了纯化的重组野生型和催化惰性IDE的作用。我们的数据表明(i)仅凭IDE即可切割未标记,碘标记或S-35-标记的纯化A beta; (ii)最初的切割位点是His(14)-Gln(15),Phe(19)-Phe(20)和Phe(20)-Ala(21); (iii)用[125I] AB而不是[S-35] -Aβ孵育IDE,会在凝胶上形成较慢的迁移物种。由于碘标记了A beta的N末端片段,而35S标记了C末端的产物,因此我们分析了未标记的A beta合成片段,并确定只有N末端片段以异常高的分子量迁移。这些结果表明,仅IDE足以在特定位点降解A beta,并且其降解产物不会促进完整A beta肽的寡聚。 [参考:42]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号